ESMO2016 Cancer market commentary: Roche’s Tecentriq muscles into NSC... Roche's PD-L1 drug has generated impressive data in second line lung cancer
News Samsung Bioepis files Herceptin biosimilar in EU South Korean firm trying to copy breast cancer blockbuster.
News NICE rejects Roche drug in follicular lymphoma NICE uncertain over survival data for Gazyvaro and bendamustine.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.